From BZ Biotech Conference: AcelRX CEO Vincent Angotti Highlights 2018 FDA Approval Of DSUVIA, Notes DoD Provided $22M Supporting Development Of Drug; Says Drug Has Been Developed With Attention To Diversion Issues And Tamper-Evident Packaging